PubMed Health⌕ Search

PubMed · 12059671

Continuum percolation for randomly oriented soft-core prisms.

Abstract

We study continuum percolation of three-dimensional randomly oriented soft-core polyhedra (prisms). The prisms are biaxial or triaxial and range in aspect ratio over six orders of magnitude. Results for prisms are compared with studies for ellipsoids, rods, ellipses, and polygons and differences are explained using the concept of the average excluded volume, . For large-shape anisotropies we find close agreement between prisms and most of the above-mentioned shapes for the critical total average excluded volume, n(c) , where n(c) is the critical number density of objects at the percolation threshold. In the extreme oblate and prolate limits simulations yield n(c) approximately 2.3 and n(c) approximately 1.3, respectively. Cubes exhibit the lowest-shape anisotropy of prisms minimizing the importance of randomness in orientation. As a result, the maximum prism value, n(c) approximately 2.79, is reached for cubes, a value close to n(c) =2.8 for the most equant shape, a sphere. Similarly, cubes yield a maximum critical object volume fraction of phi(c)=0.22. phi(c) decreases for more prolate and oblate prisms and reaches a linear relationship with respect to aspect ratio for aspect ratios greater than about 50. Curves of phi(c) as a function of aspect ratio for prisms and ellipsoids are offset at low-shape anisotropies but converge in the extreme oblate and prolate limits. The offset appears to be a function of the ratio of the normalized average excluded volume for ellipsoids over that for prisms, R= (e)/ (p). This ratio is at its minimum of R=0.758 for spheres and cubes, where phi(c(sphere))=0.2896 may be related to phi c(cube))=0.22 by phi(c(cube))=1-[1-phi(c(sphere))](R)=0.23. With respect to biaxial prisms, triaxial prisms show increased normalized average excluded volumes, , due to increased shape anisotropies, resulting in reduced values of phi(c). We confirm that B(c)=n(c) =2C(c) applies to prisms, where B(c) and C(c) are the average number of bonds per object and average number of connections per object, respectively.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Martin O Saar, Michael Manga. 2002-05-22. Continuum percolation for randomly oriented soft-core prisms.. https://doi.org/10.1103/physreve.65.056131

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗